<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139708</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00039213</org_study_id>
    <nct_id>NCT03139708</nct_id>
  </id_info>
  <brief_title>The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients</brief_title>
  <official_title>The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This an interventional study looking at two different sequences of pre-operative eye drops,
      to determine which order is more effective in reducing intraocular pressure with pupil
      dilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty healthy participants will be separated into two groups of 10 volunteers each. In both
      groups, the participant's right eye will serve as a control with only
      Tropicamide/phenylephrine given. In one group of 10 participants the left eyes will receive
      Alphagan prior to Tropicamide/phenylephrine. In the other group of 10 eyes, the left eyes
      will have Tropicamide/phenylephrine administered prior to Alphagan. The investigator will
      observe the intraocular benefits of the addition of Alphagan over the
      Tropicamide/phenylephrine alone and determine if pre-treating is any better than
      post-treating. In addition, the investigator will monitor pupil response, as it is known that
      Alphagan may have some effect on the pupil dilation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The PI measuring pupil size will not know the subject assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intraocular pressure from baseline to 15 min after last drop given, 30 min, 1 hour, and 4 hours.</measure>
    <time_frame>5 time points all occuring during one time visit: Baseline (pre drops), 15 min after last drop given, 30 min, 1 hour, and 4 hours.</time_frame>
    <description>Baseline (pre drops), 15 min after last drop given, 30 min, 1 hour, and 4 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pupil size pupil size from baseline to 15 min after last drop given, 30 min, 1 hour, and 4 hours.</measure>
    <time_frame>5 time points all occuring during one time visit: Baseline (pre drops), 15 min after last drop given, 30 min, 1 hour, and 4 hours.</time_frame>
    <description>Baseline (pre drop), 15 min after last drop given, 30 min, 1 hour, and 4 hours. The investigator will measure the pupils under bright light conditions (photopic) and dim light conditions (scotopic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pupil's reaction to light from baseline to 15 min after last drop given,30 min, 1 hour, and 4 hours.</measure>
    <time_frame>5 time points all occuring during one time visit: Baseline (pre drops), 15 min after last drop given, 30 min, 1 hour, and 4 hours.</time_frame>
    <description>Baseline (pre drop), 15 min after last drop given, 30 min, 1 hour, and 4 hours. Pupil reaction will be measure either as none, poor, or brisk.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Alphagan plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide and Phenylephrine plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide and Phenylephrine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tropicamide and Phenylephrine only arm is given one drop of each times one.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alphagan</intervention_name>
    <description>Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.</description>
    <arm_group_label>Alphagan plus</arm_group_label>
    <arm_group_label>Tropicamide and Phenylephrine plus</arm_group_label>
    <other_name>Brimonidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one.</description>
    <arm_group_label>Alphagan plus</arm_group_label>
    <arm_group_label>Tropicamide and Phenylephrine plus</arm_group_label>
    <arm_group_label>Tropicamide and Phenylephrine only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropicamide</intervention_name>
    <description>Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one.</description>
    <arm_group_label>Alphagan plus</arm_group_label>
    <arm_group_label>Tropicamide and Phenylephrine plus</arm_group_label>
    <arm_group_label>Tropicamide and Phenylephrine only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy with no major medical conditions. Contact lens wear is ok but must be not worn
             on the day of the study

        Exclusion Criteria:

          -  Diabetic, history of glaucoma

          -  history of iris trauma

          -  history of eye surgery except LASIK or Photorefractive keratectomy laser eye surgery

          -  Anisocoria

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Walter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Health Eye Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mydriasis</keyword>
  <keyword>Cycloplegics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

